Talk by Mark Evans, CEO, Adaptix Imaging Ltd (UK), at Stanford on March 7 2016, in our session: 'From Comets to Startups :: Building Europe's SpaceTech Entrepreneurship Ecosystem'. Website: http://www.StanfordEuropreneurs.org YouTube Channel: https://www.youtube.com/user/StanfordEuropreneurs Twitter: @Europreneurs

1. A transformation in X-ray technology:
3D X-ray made truly portable
Mar 7th 2016
Mark Evans, CEO
mark.evans@adaptiximaging.com
@adaptiximaging
www.adaptiximaging.com
European Entrepreneurship
Stanford Engineering

2. Field Emitters from
Field Emission Electric
Propulsion (FEEP)
- used in satellite
propulsion
X-ray Optics
- used in
X-ray telescopes
Image reconstruction
approaches used in
Earth Observation
Disrupting the >$17bn medical imaging industry
using space origin technology.

3. Vacuum tubes have been superseded in most
arenas…but not in medical imaging

4. So the X-ray Detector and IT infrastructure has
gone digital…but the source has not…yet.
• No 3D capability
• No quantification capability
• Big and bulky
• Large power need
• Expensive technology

5. • “Movement free” 3D
• Quantification
• Far lower dose than CT
• True portability
• Lower purchase and maintenance costs
• Reduced power need (normal ring main)
Our innovation: A pixilated Flat Panel X-ray
Source (FPS) that completes digitization.

6. 1. Medical [Focus]
• All: $16.9bn [2020]
• CAGR = 4.7% [2013- 2018]
• Portable: $8.4bn [2020]
+ >20 mid-tier
2. Dental [Secondary]
• All: $2.7bn [2019]
• CAGR = 9.7% [2014 to 2019]
• 3D is highest growth segment
3. Industrial [License]
• All: $652m [2020]
• CAGR = 6%
4. Security [License]
• All: $2.6bn [2020]
• CAGR = 7%

8. TREND DRIVER
Digital/Solid State Reducing cost and enhancing maintenance economics.
3D Imaging Enhancing the ability to diagnose.
Portable Taking imaging to the patient to reduce total costs.
Lower Dose Imaging is more prevalent, increasing aggregate risk.
Screening Allowing early intervention to reduce cost-to-treat.
Quantification Ascertaining disease progression and response to therapy.
Digital Tomosynthesis (DT) Obtaining 3D imaging without the cost of a CT scanner.
A series of long-term trends in diagnostic
imaging are driving the market.

9. “1.5-2.0% of all cancers in the United States may
be attributable to the radiation from CT studies.”
[1] www.nejm.org/doi/full/10.1056/NEJMra072149

10. Tomosynthesis >50% of Breast imaging market
and is emerging in General Radiology.

11. We will make low-dose 3D imaging available at
the bedside, GP clinic or in an ambulance.
Moving the point of diagnosis gives clinical and
economic advantages.

12. Portable
Planar X-ray
Planar Array Digital
Tomosynthesis
128 slice Computed
Tomography (CT)
3D Capability NO YES YES
Approximate Size Filing Cabinet Carry-on bag Small Car
Typical Dose (CXR) 0.10 mSv <0.13 mSv 1.5-8.00 mSv
Typical Cost $170,000 $100,000 $1,100,000
Cost per scan $35 <$35 $330
Typical Weight 200kg 20kg 2,000kg
Our USP is low-dose low-cost portable 3D.

13. Prototype housing and
manufacturing design
concepts complete.
Scale prototype on track for Q1 2016 will
demonstrate full performance.
Image reconstruction
approach developed.
Test Devices are
emitting X-ray.

14. 1. Hospital (Entry Mkt)
• Taking a patient from ICU to the
imaging suite takes 30 minutes for
1xDoctor + 1xNurse + 1xPorter.
2. Primary Care
• X-ray initial diagnostic for chest:
Lung Cancer, COPD, CHF.
• Use of 3D imaging can reduce
need for CT by up to 75% due to
reduction in inconclusive reads.
3. Developing World
• Low-cost low-dose DT can reduce
need for high-cost high-dose CT.
• ‘Solid state’ reduces need for
trained maintenance technicians
and a barrier for deployment.
4. Lung Screening
• >10m US smokers should be
screened annually. Up to 60% will
have abnormalities.
• Reducing screening cost from
$330 to $35 will impact viability.

15. Objectives
Seed •Scale hardware prototype.
•Reconstruction software developed to Alpha.
•Manufacturing agreements in place.
A •Regulated product ready for commercial production.
•Clinical Trial: Q4 2016
•Manufacturing and Commercial channels ready.
Growth •Working Capital for commercial production.
•Material revenues commence: Jun 2017
•Target: > $100m run-rate < 3 years from launch.
Looking for US investors to assist a ‘flip’ in to
becoming a US company to drive exit value.

16. A transformation in X-ray technology:
3D X-ray made truly portable
Mar 7th 2016
Mark Evans, CEO
mark.evans@adaptiximaging.com
@adaptiximaging
www.adaptiximaging.com
European Entrepreneurship
Stanford Engineering